{"name":"Walter K. Kraft","slug":"walter-k-kraft","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Doravirine (DOR)","genericName":"Doravirine (DOR)","slug":"doravirine-dor","indication":"HIV-1 infection in treatment-naïve and treatment-experienced adults (in combination antiretroviral therapy)","status":"marketed"},{"name":"Rifapentine (RPT)","genericName":"Rifapentine (RPT)","slug":"rifapentine-rpt","indication":"Tuberculosis (TB), including drug-susceptible and latent TB infection","status":"phase_3"}]}],"pipeline":[{"name":"Doravirine (DOR)","genericName":"Doravirine (DOR)","slug":"doravirine-dor","phase":"marketed","mechanism":"Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV reverse transcriptase to prevent viral replication.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced adults (in combination antiretroviral therapy)"],"catalyst":""},{"name":"Rifapentine (RPT)","genericName":"Rifapentine (RPT)","slug":"rifapentine-rpt","phase":"phase_3","mechanism":"Rifapentine inhibits bacterial RNA polymerase, preventing transcription and killing or stopping the growth of mycobacteria.","indications":["Tuberculosis (TB), including drug-susceptible and latent TB infection","Pulmonary tuberculosis as part of combination therapy"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE9aX3VhLUY0d2U3a1dmZGZJcXFQU2lPVVZTMldhSXRyLWotaU5OZGtwUHliSzd1c1hvWEN0NUdmR3ExY1pOTlF2bU5XbjcyY0tMS013R1MyYTdNR3hmcG1FeExkX1l0MFFzRzljeXpoQVdPQQ?oc=5","date":"2025-03-04","type":"trial","source":"Wiley","summary":"Pharmacodynamics of Aspirin Through Gestation: Predictors of Aspirin Response and Association With Pregnancy Outcome, a Prospective Cohort Study - Wiley","headline":"Pharmacodynamics of Aspirin Through Gestation: Predictors of Aspirin Response and Association With Pregnancy Outcome, a ","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":1,"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}